TORONTO, Feb. 2, 2021/ PRNewswire/– MindMed (NEO: MMED, OTCQB: MMEDF, DE: MMQ), a leading psychedelic medication biotech business, structured its management group to additional establish the business’s technique of incorporating its psychedelic scientific advancement programs with ingenious digital innovations.
As part of this, Stephen Hurst will retire from his co-CEO and Executive Chair positions however will stay on the board of directors. Dr. Glick has actually retired from his position on the board of directors however will continue to function as a clinical consultant. The job on the board of directors developed by Dr. Glick’s retirement will be filled by the board after finishing a comprehensive search and interview procedure for ideal prospects and as needed as part of its NASDAQ uplisting application.
J.R. Rahn will handle sole duty as Ceo of the Business and Perry Dellelce has actually been designated as Chair of the board of directors. This advancement of executive management will reinforce MindMed’s technique with a group that consists of Dr. Miri Wernli Halperin as President and Head of Medical and Carol Nast as Chief Operating Officer, along with Robert Barrow who was just recently employed as Chief Advancement Officer to broaden on the business’s later phase scientific trial pipeline and drug advancement efforts at the FDA. Prior to signing up with MindMed, Robert Barrow assisted acquire an Advancement Treatment Classification for a Stage 2 trial of psilocybin in Significant Depressive Condition at the FDA.